Evidence map›Paper›PMID 38361041›Full record

ArticleNature materials2024

Immunoengineering can overcome the glycocalyx armour of cancer cells.

Sangwoo Park, Marshall J Colville, Justin H Paek, Carolyn R Shurer, Arun Singh, Erica J Secor, Cooper J Sailer, Ling-Ting Huang, Joe Chin-Hun Kuo, Marc C Goudge and 9 more

Open access · greenAbstract read
In one paragraph

Article in Nature materials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
8.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 38 citations in OpenAlex.

  1. Discovery of a secretedGut microbes · 2026
    Article
  2. Article
  3. Review
  4. Review
  5. Engineering CAR-T cells to remodel the mucin-rich cancer cell glycocalyx.bioRxiv : the preprint server for biology · 2026
    Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. The protease cathepsin K can debulk the cancer glycocalyx.The Journal of biological chemistry · 2026
    Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 1 country.

Sangwoo ParkField of Biophysics, Cornell University, Ithaca, NY, USA.ORCID 0000-0002-2701-3114
Marshall J ColvilleField of Biophysics, Cornell University, Ithaca, NY, USA.
Justin H PaekNancy E. and Peter C. Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY, USA.
Carolyn R ShurerRobert Frederick Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, NY, USA.
Arun SinghState University of New York, Buffalo, NY, USA.ORCID 0000-0001-9036-1608
Erica J SecorDepartment of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, USA.ORCID 0000-0002-9091-5444
Cooper J SailerDepartment of Pathology, University of Rochester Medical Center, Rochester, NY, USA.ORCID 0000-0001-8055-588X
Ling-Ting HuangRobert Frederick Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, NY, USA.ORCID 0009-0004-4343-6039
Joe Chin-Hun KuoRobert Frederick Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, NY, USA.
Marc C GoudgeNancy E. and Peter C. Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY, USA.
Jin SuDepartment of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, USA.
Minsoo KimDepartment of Microbiology and Immunology, David H. Smith Center for Vaccine Biology and Immunology, University of Rochester Medical Center, Rochester, NY, USA.
Matthew P DeLisaRobert Frederick Smith School of Chemical and Biomolecular Engineering, Cornell University, Ithaca, NY, USA.
Sriram NeelameghamState University of New York, Buffalo, NY, USA.ORCID 0000-0002-1371-8500
Jan LammerdingNancy E. and Peter C. Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY, USA.ORCID 0000-0003-4335-8611
Warren R ZipfelField of Biophysics, Cornell University, Ithaca, NY, USA.ORCID 0000-0003-2640-329X
Claudia FischbachNancy E. and Peter C. Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY, USA.ORCID 0000-0002-9368-0150
Heidi L ReesinkDepartment of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, USA.
Matthew J PaszekField of Biophysics, Cornell University, Ithaca, NY, USA. mjp31@cornell.edu.ORCID 0000-0003-0064-9400
Cornell University · USUniversity at Buffalo, State University of New York · USUniversity of Rochester Medical Center · US

Funding

Project 3: Physical and Metabolic Constraints of Cancer Cell InvasionU54CA210184 · NCI · CORNELL UNIVERSITY · PI CANTLEY, LEWIS C., FISCHBACH, CLAUDIA · 2016 to 2020
$10.2M
The T32 Predoctoral Training Program in Immunology (PTPI)T32AI007285 · NIAID · UNIVERSITY OF ROCHESTER · PI Scott Andrew Gerber, JACQUES Robert · 1986 to 2026
$7.6M
T cell migration and cardiovascular toxicity in immunotherapyR01AI147362 · NIAID · UNIVERSITY OF ROCHESTER · PI Minsoo Kim, Richard E Waugh · 2019 to 2026
$4.2M
Truncated O-glycan-dependent mechanisms inducing metastatic dissemination in pancreatic cancerR01CA273349 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BATRA, SURINDER K., PONNUSAMY, MOORTHY P. · 2022 to 2025
$2.7M
Mechanobiology of the Cellular GlycocalyxDP2GM119133 · NIGMS · CORNELL UNIVERSITY · PI PASZEK, MATTHEW J · 2015 to 2015
$2.3M
Molecular toolkit for high content resolution of glycomes by expansionmicroscopyR01GM137314 · NIGMS · CORNELL UNIVERSITY · PI ALABI, CHRISTOPHER AKINLEYE, DELISA, MATTHEW P · 2020 to 2023
$1.8M
Physical Resistance to Immune Cell Attack by the Cellular GlycocalyxR01CA276398 · NCI · CORNELL UNIVERSITY · PI Matthew J Paszek · 2023 to 2026
$1.8M
Biophysical regulation of intercellular communication by the glycocalyxR01GM138692 · NIGMS · CORNELL UNIVERSITY · PI PASZEK, MATTHEW J · 2020 to 2023
$1.3M
Fast interference-based super-resolution microscope for cancer mechanobiologyR33CA193043 · NCI · CORNELL UNIVERSITY · PI ZIPFEL, WARREN R · 2015 to 2017
$1.1M
Broad wavelength range Zeiss 780 NLO/confocal system for the Cornell Imaging CoreS10OD018516 · OD · CORNELL UNIVERSITY · PI ZIPFEL, WARREN R · 2014 to 2014
$834k
NCI NIH HHS R01 CA273349NCI NIH HHS R01 CA276398NCI NIH HHS R33 CA193043NCI NIH HHS U54 CA210184NIAID NIH HHS R01 AI147362NIAID NIH HHS T32 AI007285NIGMS NIH HHS DP2 GM119133NIGMS NIH HHS R01 GM137314NIGMS NIH HHS R01 GM138692NIH HHS S10 OD018516
6 · The paper itself

Abstract

Cancer cell glycocalyx is a major line of defence against immune surveillance. However, how specific physical properties of the glycocalyx are regulated on a molecular level, contribute to immune evasion and may be overcome through immunoengineering must be resolved. Here we report how cancer-associated mucins and their glycosylation contribute to the nanoscale material thickness of the glycocalyx and consequently modulate the functional interactions with cytotoxic immune cells. Natural-killer-cell-mediated cytotoxicity is inversely correlated with the glycocalyx thickness of the target cells. Changes in glycocalyx thickness of approximately 10 nm can alter the susceptibility to immune cell attack. Enhanced stimulation of natural killer and T cells through equipment with chimeric antigen receptors can improve the cytotoxicity against mucin-bearing target cells. Alternatively, cytotoxicity can be enhanced through engineering effector cells to display glycocalyx-editing enzymes, including mucinases and sialidases. Together, our results motivate the development of immunoengineering strategies that overcome the glycocalyx armour of cancer cells.

Indexed as

Antineoplastic AgentsNeoplasmsGlycocalyxHumansMucinsAntineoplastic AgentsMucins

Identifiers

PMID38361041
PMCPMC11471287
OpenAlexW4391840637

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.